A child with ADA deficiency is treated by gene therapy. Lymphocytes from her blood are grown in culture, a functional ADA cDNA is introduced into them using a retroviral vector, and the cells are returned to her. Her immune function improves.
Several months later, tests show that her immune function is falling again, although the treatment had worked as planned. What is the most likely explanation, and what does it mean for her treatment?

